Here’s what you need to know.
1. The U.S. Justice Department and other agencies have not confirmed the settlement.
2. Mylan said it is now in the final stage of closing its settlement.
3. The Justice Department is investing Mylan over its decision to raise the costs of its EpiPen. The EpiPen projects to account for 6 percent of Mylan’s total sales in 2017.
More articles on coding, billing and collections:
MACRA patient engagement cheat sheet No. 1 — Leveraging patient engagement for MACRA success: An overview
Colorado rejects single-payer healthcare system — 4 points
10 key steps to immediately improve ASC finances
